Category: Mergers & Acquisitions
Siemens is in advanced talks to sell its hearing-aids business to private equity shop EQT, unnamed sources tell Reuters.
Sorin Group drops $20 million on a stake in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
Sorin Group (BIT:SRN) said it invested $20 million in a minority stake and controlling option in Minnetonka, Minn.-based Respicardia, which is developing implantable devices to treat central sleep apnea.
Abbott says it will go ahead with its plan to deal its generic pharmaceuticals line to Mylan for $5.3 billion and reports 3rd-quarter sales in line with expectations.
Shares of Medtronic and Covidien gain after Medtronic affirms its $43 billion acquisition plans, saying it now expects to close the deal for Covidien late this year or early in 2015.
Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit
, Becton Dickinson & Co.
, DePuy Synthes
, GenCell Biosystems
, Johnson & Johnson
, Kimberly-Clark Worldwide Inc.
, MAKO Surgical Corp.
, Stryker Corp.
, Valeant Pharmaceuticals
, 3M Corp.
, Allergan Inc.
Allergan says there's no evidence to back claims by hostile suitors Valeant Pharmaceuticals and hedge mogul William Ackman's Pershing Square Capital Management that Allergan CEO David Pyott led a smear campaign against them.
Valeant Pharmaceuticals says it might up the ante in its hostile takeover bid for Allergan as it reports higher-than-forecast profits for its 3rd quarter.